Developer docs
API playgroundTry for free, no card

Search company profiles

Catalio Capital Management

Full company profile

uuid00000d6

Namestring
Catalio Capital Management
Legal namestring
Catalio Capital Management, LP
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare companies across the full investment lifecycle — private equity, structured credit, public equities, and co-investments. Founded in 2020 by Johns Hopkins alumni George C. Petrocheilos and R. Jacob Vogelstein, Ph.D., the firm serves institutional limited partners and family offices seeking specialist healthcare exposure. As of October 1, 2025, Catalio reported $2 billion in assets under management, with $2.3 billion in healthcare assets under management within its public equities strategy, and has distributed nearly $300 million to investors since 2020 in a market where 79% of venture capital funds raised since 2020 reportedly returned $0 to investors. The firm employs 40+ people across offices in New York City, Washington DC, and London, with Asia coverage led by Partner Hai Yan, Ph.D. in Singapore. KKR acquired a minority stake in October 2023, and KKR Co-Founder Henry Kravis serves as Chairman of Catalio's Board of Advisors.

The firm's investment platform comprises four core strategies: Private Equity (venture capital) backing innovative drugs, AI-enabled companies, medical devices, and diagnostics; Structured Opportunities (structured credit) targeting commercial-stage healthcare companies with $10M–$50M deals; Public Equities (a healthcare-focused public fund launched in 2023); and Co-Investments. Catalio's primary differentiator is a proprietary expert network of 45+ scientist-entrepreneur Venture Partners — including Nobel laureates Jim Allison, Thomas Südhof, Gregg Semenza, Frances Arnold, and Adam Riess — collectively credited with founding 171 companies and holding 12 Nobel and Breakthrough Prizes. The firm is building human-augmented investment platforms powered by a newly created data-science function led by a former Citadel/Coatue executive, applying AI to support investing across private, public, and credit healthcare markets.

Catalio generates revenue through traditional private-fund economics: management fees on committed/invested capital across multiple vehicles — including the ~$400M Fund IV, the $325M Structured Opportunities Fund II, and the public equities fund — plus performance-based carried interest. Distribution combines direct institutional private placement to LPs with separately managed accounts, most notably a $200 million allocation from macro hedge fund Brevan Howard in June 2026. Materials are reserved for financially sophisticated investors and distributed via password-protected SEI and MSFS investor portals under Securities Act private placement exemptions; the firm is not registered with the SEC as an investment adviser.

Short descriptiontext

Catalio Capital Management is a New York-based investment firm managing $2B in assets across private equity, structured credit, public equities, and co-investments, serving institutional limited partners with specialist healthcare exposure sourced from a 45+ scientist-entrepreneur Venture Partner network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, biomedical investment management, structured credit funds, private equity healthcare, institutional asset management
Industry3 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms
SECONDARYFSAAAHAH
Structured Credit (CDO/CLO Tranches, Credit Opportunities)
Financial & Insurance/Asset & Wealth Management/Asset Management — Fixed Income & Credit
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Investment Management
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fund Management Fees & Carried Interest
TypeManaged Services
Description

Catalio generates revenue through traditional private-fund economics: management fees on committed/invested capital across multiple vehicles (including Private Equity funds, Structured Opportunities Fund II, Fund IV) plus performance-based carried interest on investment gains. The firm has distributed nearly $300M to investors from its Funds and SPVs over the period since 2020.

cataliocapital.com
2Separately Managed Accounts (SMAs)
TypeManaged Services
Description

Execution-style SMA mandates (e.g., Brevan Howard's $200M allocation into Catalio's healthcare-focused public equities fund) where Catalio executes trades while the client retains risk controls — generating fee revenue without balance-sheet exposure.

bitget.com
3Structured Credit Interest & Fees
TypeSubscription Recurring
Description

Targeted structured credit investments ($10M–$50M deals) into commercial-stage healthcare companies, generating interest income and structuring fees as an alternative to dilutive equity financing; the strategy has completed 21 investments to date.

finance.yahoo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
Pricing details1 tier
1Private placement fund terms — not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Materials are intended only for financially sophisticated investors; minimums, management fees, hurdle rates, and carry are negotiated bilaterally and stated in confidential offering documents.

cataliocapital.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Catalio Venture Partners
Description

Network of 45+ world-renowned scientist-entrepreneurs who serve as Catalio's proprietary expert network for scientific due diligence and provide differentiated insight, specialized expertise across sectors, and extensive track record of success.

cataliocapital.com
+1 more record
Core offering1 text field

Catalio Capital Management is a New York-based investment firm that manages capital across the full lifecycle of innovative healthcare companies, spanning private equity (venture capital), structured credit opportunities, public equities, and co-investments. The firm raises capital from institutional limited partners and family offices via private placement of dedicated fund vintages, deploying that capital into drugs, AI-enabled healthcare, devices, diagnostics, and related biomedical technology companies. Investment decisions are supported by a proprietary network of 45+ scientist-entrepreneur Venture Partners who provide deal flow and scientific due diligence.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 49% net return on healthcare-focused public equities fund since its 2023 launch
+5 more records
Product overview1 text field

Catalio Capital Management is a New York-based investment firm (not a traditional technology product company) that offers a platform of four core investment strategies under one unified firm: Private Equity (Venture Capital), Structured Opportunities, Public Equities, and Co-Investments. These strategies work together to provide full lifecycle healthcare investing across private, public, and credit markets, with $2B+ in assets under management, 40+ employees, 45+ Venture Partners, and a portfolio spanning drugs, AI-enabled companies, devices, diagnostics, and other healthcare categories. While Catalio's offerings are investment strategies rather than software products, the firm is building AI-augmented investment platforms internally to support its portfolio analysis and due diligence processes.

Product and service5 records
1Private Equity (Venture Capital)
CategoryInvestment Strategy
Description

Flagship venture capital strategy investing in innovative healthcare companies across drugs, AI-enabled companies, devices, diagnostics, and other categories; portfolio includes Arrivent, ATAI Life Sciences, Compass, Dianthus, Recursion, Neumora, and others across the full healthcare lifecycle. For institutional limited partners.

2Structured Opportunities
CategoryInvestment Strategy
Description

Structured credit strategy targeting commercial-stage healthcare companies seeking structured capital as an alternative to dilutive equity financing; Catalio Structured Opportunities Fund II raised more than $325M, exceeding its $250M target, and has completed 21 investments to date. For institutional limited partners.

3Public Equities
CategoryInvestment Strategy
Description

Healthcare-focused public equities fund managing $2.3 billion in healthcare assets spanning pharmaceuticals, medical devices, diagnostics, and data companies; has delivered a 49% net return since its 2023 launch. For institutional limited partners and multi-manager platforms.

4Co-Investments
CategoryInvestment Strategy
Description

Co-investment strategy providing investors with opportunities to participate alongside Catalio's lead investments in innovative healthcare companies across all stages and sizes throughout the capital structure. For institutional limited partners.

5Separately Managed Accounts (SMAs)
CategoryInvestment Strategy
Description

Execution-style separately managed account mandates where Catalio executes trades on a healthcare-focused public-equities strategy while the institutional client retains risk controls; generates fee revenue without balance-sheet exposure. For multi-manager hedge fund platforms.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Henry Kravis (Co-Founder & Co-Chairman, KKR & Co.)
Strategic tierFlagshipTypeOthers
Description

Henry Kravis serves as Chairman of Catalio's Board of Advisors. The board includes other marquee institutional figures including Orlando Bravo (Founder & Managing Partner, Thoma Bravo), Jim Breyer (Founder & CEO, Breyer Capital), Michael Buckley (Managing Director, Duquesne Family Office), Glenn Dubin (Founder & Principal, Dubin & Co.), Isabelle Ealet (Partner & Co-Head, Securities Division, Goldman Sachs), Alex Gorsky (Chairman & CEO Retired, Johnson & Johnson), and Tim O'Neill (Partner & Co-Head of Goldman Sachs Asset Management Ret.).

cataliocapital.com
2Catalio Venture Partner Network (45+ scientist-entrepreneurs)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Network of 45+ world-renowned, serial scientist-entrepreneurs who provide proprietary deal flow, scientific due diligence, advisory on emerging biomedical trends, and sector-specialized expertise. The collective network has founded 171 companies and holds 12 Nobel & Breakthrough Prizes, with members including Nobel laureates Jim Allison (immunology), Thomas Südhof (neuroscience), Gregg Semenza (oxygen biology), Frances Arnold (chemistry), Adam Riess (physics), and Turing Award-related figures.

cataliocapital.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

OrbiMed is a healthcare-dedicated investment firm investing across private equity, public equity, and royalty/credit vehicles — directly comparable to Catalio's full-lifecycle, full-capital-structure healthcare platform and similar sector focus.

TypeDirect peer
Description

RA Capital is a healthcare-focused multi-stage fund manager that runs both private and public equities strategies — closely mirroring Catalio's combination of healthcare PE and a 49%-returning public equities fund.

TypeDirect peer
Description

ARCH is a long-tenured life sciences and breakthrough-technology venture firm with a scientist-founded model, directly comparable to Catalio's emphasis on Nobel-grade scientific Venture Partners and breakthrough biomedical deal flow.

TypeDirect peer
Description

Versant is a healthcare-focused venture capital firm operating across stages, including a dedicated credit/structured capital arm — directly comparable to Catalio's PE + Structured Opportunities + Co-Investments platform.

TypeDirect peer
Description

Atlas Venture is an early-stage life sciences-focused venture firm building biotech companies, comparable to Catalio's life sciences venture strategy and its Venture-Partner-led company-creation model.

TypeDirect peer
Description

Flagship Pioneering is a science-driven venture creation firm that founds and funds breakthrough biomedical companies, comparable to Catalio's biomedical specialization and its scientist-entrepreneur network-led origination.

TypeDirect peer
Description

5AM Ventures is a life sciences-focused venture capital firm investing across early and late stages in biotech and medtech — directly comparable to Catalio's stage-agnostic healthcare venture strategy.

TypeBroad incumbent
Description

NEA is a large, multi-sector venture capital firm with a substantial healthcare practice — comparable to Catalio on healthcare investing but with a much broader sector mandate and far larger AUM.

TypeDirect peer
Description

Cormorant is a healthcare-focused investment manager running long/short public equities with private/venture exposure, closely mirroring Catalio's specialist healthcare public-equities plus private investment approach.

10Baker Bros. Advisors
TypeDirect peer
Description

Baker Bros. is a long-tenured, healthcare-only specialist managing both long-only public equities and private investments, directly comparable to Catalio's healthcare-specialist, multi-strategy model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles32 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment155 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Catalio Capital Management

Healthcare Investment Managementcataliocapital.com

Catalio Capital Management is a New York-based investment firm managing $2B in assets across private equity, structured credit, public equities, and co-investments, serving institutional limited partners with specialist healthcare exposure sourced from a 45+ scientist-entrepreneur Venture Partner network.

What Catalio Capital Management does

Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare companies across the full investment lifecycle — private equity, structured credit, public equities, and co-investments. Founded in 2020 by Johns Hopkins alumni George C. Petrocheilos and R. Jacob Vogelstein, Ph.D., the firm serves institutional limited partners and family offices seeking specialist healthcare exposure. As of October 1, 2025, Catalio reported $2 billion in assets under management, with $2.3 billion in healthcare assets under management within its public equities strategy, and has distributed nearly $300 million to investors since 2020 in a market where 79% of venture capital funds raised since 2020 reportedly returned $0 to investors. The firm employs 40+ people across offices in New York City, Washington DC, and London, with Asia coverage led by Partner Hai Yan, Ph.D. in Singapore. KKR acquired a minority stake in October 2023, and KKR Co-Founder Henry Kravis serves as Chairman of Catalio's Board of Advisors.

The firm's investment platform comprises four core strategies: Private Equity (venture capital) backing innovative drugs, AI-enabled companies, medical devices, and diagnostics; Structured Opportunities (structured credit) targeting commercial-stage healthcare companies with $10M–$50M deals; Public Equities (a healthcare-focused public fund launched in 2023); and Co-Investments. Catalio's primary differentiator is a proprietary expert network of 45+ scientist-entrepreneur Venture Partners — including Nobel laureates Jim Allison, Thomas Südhof, Gregg Semenza, Frances Arnold, and Adam Riess — collectively credited with founding 171 companies and holding 12 Nobel and Breakthrough Prizes. The firm is building human-augmented investment platforms powered by a newly created data-science function led by a former Citadel/Coatue executive, applying AI to support investing across private, public, and credit healthcare markets.

Catalio generates revenue through traditional private-fund economics: management fees on committed/invested capital across multiple vehicles — including the ~$400M Fund IV, the $325M Structured Opportunities Fund II, and the public equities fund — plus performance-based carried interest. Distribution combines direct institutional private placement to LPs with separately managed accounts, most notably a $200 million allocation from macro hedge fund Brevan Howard in June 2026. Materials are reserved for financially sophisticated investors and distributed via password-protected SEI and MSFS investor portals under Securities Act private placement exemptions; the firm is not registered with the SEC as an investment adviser.

Catalio Capital Management firmographics

Firmographics
Name
Catalio Capital Management
Legal name
Catalio Capital Management, LP
Website
https://cataliocapital.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Catalio Capital Management is a New York-based investment firm managing $2B in assets across private equity, structured credit, public equities, and co-investments, serving institutional limited partners with specialist healthcare exposure sourced from a 45+ scientist-entrepreneur Venture Partner network.
Ownership category
akta.pro rank

Catalio Capital Management industry classification

Industry
Product category
Healthcare Investment Management
NAICS
Portfolio Management and Investment Advice (523940), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms
SECONDARYFSAAAHAH
Structured Credit (CDO/CLO Tranches, Credit Opportunities)
Financial & Insurance/Asset & Wealth Management/Asset Management — Fixed Income & Credit

Keywords

  • Healthcare venture capital
  • Biomedical investment management
  • Structured credit funds
  • Private equity healthcare
  • Institutional asset management

Where Catalio Capital Management is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Catalio Capital Management business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

  1. Fund Management Fees & Carried Interest: Catalio generates revenue through traditional private-fund economics: management fees on committed/invested capital across multiple vehicles (including Private Equity funds, Structured Opportunities Fund II, Fund IV) plus performance-based carried interest on investment gains. The firm has distributed nearly $300M to investors from its Funds and SPVs over the period since 2020.
  2. Separately Managed Accounts (SMAs): Execution-style SMA mandates (e.g., Brevan Howard's $200M allocation into Catalio's healthcare-focused public equities fund) where Catalio executes trades while the client retains risk controls — generating fee revenue without balance-sheet exposure.
  3. Structured Credit Interest & Fees: Targeted structured credit investments ($10M–$50M deals) into commercial-stage healthcare companies, generating interest income and structuring fees as an alternative to dilutive equity financing; the strategy has completed 21 investments to date.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPrivate placement fund terms — not publicly disclosed

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Catalio Capital Management product offering

Product offering

Core offering

Catalio Capital Management is a New York-based investment firm that manages capital across the full lifecycle of innovative healthcare companies, spanning private equity (venture capital), structured credit opportunities, public equities, and co-investments. The firm raises capital from institutional limited partners and family offices via private placement of dedicated fund vintages, deploying that capital into drugs, AI-enabled healthcare, devices, diagnostics, and related biomedical technology companies. Investment decisions are supported by a proprietary network of 45+ scientist-entrepreneur Venture Partners who provide deal flow and scientific due diligence.

Product overview

Catalio Capital Management is a New York-based investment firm (not a traditional technology product company) that offers a platform of four core investment strategies under one unified firm: Private Equity (Venture Capital), Structured Opportunities, Public Equities, and Co-Investments. These strategies work together to provide full lifecycle healthcare investing across private, public, and credit markets, with $2B+ in assets under management, 40+ employees, 45+ Venture Partners, and a portfolio spanning drugs, AI-enabled companies, devices, diagnostics, and other healthcare categories. While Catalio's offerings are investment strategies rather than software products, the firm is building AI-augmented investment platforms internally to support its portfolio analysis and due diligence processes.

Differentiator

Problem solved

Functional benefit

Brands

  • Catalio Venture Partners: Network of 45+ world-renowned scientist-entrepreneurs who serve as Catalio's proprietary expert network for scientific due diligence and provide differentiated insight, specialized expertise across sectors, and extensive track record of success.
  • Catalio Structured Opportunities Fund

Products and services

  • Private Equity (Venture Capital) Flagship venture capital strategy investing in innovative healthcare companies across drugs, AI-enabled companies, devices, diagnostics, and other categories; portfolio includes Arrivent, ATAI Life Sciences, Compass, Dianthus, Recursion, Neumora, and others across the full healthcare lifecycle. For institutional limited partners.
  • Structured Opportunities Structured credit strategy targeting commercial-stage healthcare companies seeking structured capital as an alternative to dilutive equity financing; Catalio Structured Opportunities Fund II raised more than $325M, exceeding its $250M target, and has completed 21 investments to date. For institutional limited partners.
  • Public Equities Healthcare-focused public equities fund managing $2.3 billion in healthcare assets spanning pharmaceuticals, medical devices, diagnostics, and data companies; has delivered a 49% net return since its 2023 launch. For institutional limited partners and multi-manager platforms.
  • Co-Investments Co-investment strategy providing investors with opportunities to participate alongside Catalio's lead investments in innovative healthcare companies across all stages and sizes throughout the capital structure. For institutional limited partners.
  • Separately Managed Accounts (SMAs) Execution-style separately managed account mandates where Catalio executes trades on a healthcare-focused public-equities strategy while the institutional client retains risk controls; generates fee revenue without balance-sheet exposure. For multi-manager hedge fund platforms.

Quantifiable outcome

  • 49% net return on healthcare-focused public equities fund since its 2023 launch
  • +5 more outcomes

Companies that use Catalio Capital Management

Customer profile

Segments3 records

Ideal customer profiles3 records

Catalio Capital Management technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Catalio Capital Management partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship.

  • Henry Kravis (Co-Founder & Co-Chairman, KKR & Co.)flagshipOthersHenry Kravis serves as Chairman of Catalio's Board of Advisors. The board includes other marquee institutional figures including Orlando Bravo (Founder & Managing Partner, Thoma Bravo), Jim Breyer (Founder & CEO, Breyer Capital), Michael Buckley (Managing Director, Duquesne Family Office), Glenn Dubin (Founder & Principal, Dubin & Co.), Isabelle Ealet (Partner & Co-Head, Securities Division, Goldman Sachs), Alex Gorsky (Chairman & CEO Retired, Johnson & Johnson), and Tim O'Neill (Partner & Co-Head of Goldman Sachs Asset Management Ret.).
  • Catalio Venture Partner Network (45+ scientist-entrepreneurs)flagshipStrategic or Co-development PartnerNetwork of 45+ world-renowned, serial scientist-entrepreneurs who provide proprietary deal flow, scientific due diligence, advisory on emerging biomedical trends, and sector-specialized expertise. The collective network has founded 171 companies and holds 12 Nobel & Breakthrough Prizes, with members including Nobel laureates Jim Allison (immunology), Thomas Südhof (neuroscience), Gregg Semenza (oxygen biology), Frances Arnold (chemistry), Adam Riess (physics), and Turing Award-related figures.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Catalio Capital Management competitors and assessment

Company assessment

Direct peers

  • OrbiMed Advisors: OrbiMed is a healthcare-dedicated investment firm investing across private equity, public equity, and royalty/credit vehicles — directly comparable to Catalio's full-lifecycle, full-capital-structure healthcare platform and similar sector focus.
  • RA Capital Management: RA Capital is a healthcare-focused multi-stage fund manager that runs both private and public equities strategies — closely mirroring Catalio's combination of healthcare PE and a 49%-returning public equities fund.
  • ARCH Venture Partners: ARCH is a long-tenured life sciences and breakthrough-technology venture firm with a scientist-founded model, directly comparable to Catalio's emphasis on Nobel-grade scientific Venture Partners and breakthrough biomedical deal flow.
  • Versant Ventures: Versant is a healthcare-focused venture capital firm operating across stages, including a dedicated credit/structured capital arm — directly comparable to Catalio's PE + Structured Opportunities + Co-Investments platform.
  • Atlas Venture: Atlas Venture is an early-stage life sciences-focused venture firm building biotech companies, comparable to Catalio's life sciences venture strategy and its Venture-Partner-led company-creation model.
  • Flagship Pioneering: Flagship Pioneering is a science-driven venture creation firm that founds and funds breakthrough biomedical companies, comparable to Catalio's biomedical specialization and its scientist-entrepreneur network-led origination.
  • 5AM Ventures: 5AM Ventures is a life sciences-focused venture capital firm investing across early and late stages in biotech and medtech — directly comparable to Catalio's stage-agnostic healthcare venture strategy.
  • Cormorant Asset Management: Cormorant is a healthcare-focused investment manager running long/short public equities with private/venture exposure, closely mirroring Catalio's specialist healthcare public-equities plus private investment approach.
  • Baker Bros. Advisors: Baker Bros. is a long-tenured, healthcare-only specialist managing both long-only public equities and private investments, directly comparable to Catalio's healthcare-specialist, multi-strategy model.

Broad incumbents

  • New Enterprise Associates (NEA): NEA is a large, multi-sector venture capital firm with a substantial healthcare practice — comparable to Catalio on healthcare investing but with a much broader sector mandate and far larger AUM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Catalio Capital Management social profiles

Digital presence

Catalio Capital Management financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Catalio Capital Management leadership team

Management profile

Number of profiles

Profiles32 records

Catalio Capital Management subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Catalio Capital Management funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Catalio Capital Management M&A and investment

M&A and investment

M&A2 records

Investments155 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Catalio Capital Management

What does Catalio Capital Management do?

Catalio Capital Management is a New York-based investment firm that manages capital across the full lifecycle of innovative healthcare companies, spanning private equity (venture capital), structured credit opportunities, public equities, and co-investments. The firm raises capital from institutional limited partners and family offices via private placement of dedicated fund vintages, deploying that capital into drugs, AI-enabled healthcare, devices, diagnostics, and related biomedical technology companies. Investment decisions are supported by a proprietary network of 45+ scientist-entrepreneur Venture Partners who provide deal flow and scientific due diligence.

Is Catalio Capital Management a public or private company?

Catalio Capital Management is a private company. It is classified as venture growth investor backed and is currently operating.

When was Catalio Capital Management founded?

Catalio Capital Management was founded in 2020. It employs 11 to 50 people.

Where is Catalio Capital Management based?

Catalio Capital Management is headquartered in New York, United States, in the North America region.

How does Catalio Capital Management make money?

Three revenue lines are on record. Fund Management Fees & Carried Interest is the primary driver. The others are separately Managed Accounts (SMAs) and structured Credit Interest & Fees.

Who are Catalio Capital Management's main competitors?

Direct peers on record are OrbiMed Advisors, RA Capital Management, ARCH Venture Partners, Versant Ventures, Atlas Venture, Flagship Pioneering, 5AM Ventures, Cormorant Asset Management and Baker Bros. Advisors. New Enterprise Associates (NEA) is listed as a broad incumbent.

Does Catalio Capital Management have an API?

No public API is recorded for Catalio Capital Management.

What industry is Catalio Capital Management in?

Catalio Capital Management's product category is Healthcare Investment Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VC News DailyZAP Surgical Secures $36 MillionZAP Surgical Systems secured $36 million in financing led by Catalio Capital Management, with continued support from Baheal. The funding reflects investor confidence in its non-invasive robotic brain surgery technology and commercial momentum.Medical BuyerZAP Surgical secures USD 36M in fundingZAP Surgical secured $36 million in financing led by Catalio Capital Management, with Baheal support. The capital will fund global expansion of its ZAP-X radiosurgery platform, which has treated nearly 10,000 patients. The company is scaling production and planning multi-center trials for psychiatric disorders.Startup ResearcherZAP Surgical Secures $36 Million for Robotic Radiosurgery ExpansionZAP Surgical Systems closed a $36 million financing round led by Catalio Capital Management, with Baheal participating. The capital will support global expansion, production capacity, and clinical research for psychiatric disorders. The company has treated nearly 10,000 patients with its ZAP-X platform.EIN PresswireZAP Surgical Secures $36M to Expand Robotic Brain SurgeryZAP Surgical secured $36 million in financing led by Catalio Capital Management to expand its robotic radiosurgery platform. The company has shipped its 50th system and treated nearly 10,000 patients. It plans to pursue radiomodulation research and multicentre clinical trials.VentureburnZAP Surgical Secures $36M to Expand Robotic Brain SurgeryZAP Surgical secured $36 million in financing led by Catalio Capital Management to expand its ZAP-X radiosurgery platform globally. The company has shipped its 50th system and treated nearly 10,000 patients. It is also exploring radiomodulation for treatment-resistant depression and addiction.BitlyZap Surgical Raises $36M in Funding to Scale Non-Invasive Robotic Brain SurgeryZap Surgical raised $36 million in financing led by Catalio Capital Management to expand production and deployment of its ZAP-X robotic radiosurgery platform. The company shipped its 50th ZAP-X system and has treated nearly 10,000 patients worldwide. It is also studying radiomodulation for psychiatric conditions, with larger multicenter trials planned.FinancialContent Business PageZAP Surgical Secures $36 Million Led by Catalio Capital Management to Scale Non-Invasive Brain SurgeryZAP Surgical secured $36 million in financing led by Catalio Capital Management to scale its ZAP-X radiosurgery platform. The company shipped its 50th ZAP-X system and has treated nearly 10,000 patients worldwide. It plans multi-center trials for psychiatric disorders like treatment-resistant depression.Investing.comCatalio Capital seeks $500 million for AI healthcare startups - BloombergCatalio Capital Management, backed by KKR, is seeking $500 million for its second fund, accelerating the Nexus V launch from 2027. The fund will invest in AI healthcare startups, with five existing investments rolled in, including Doctronic and Basecamp Research. The firm's most recent fund closed in July 2025 with over $400 million.Investing.comCatalio Capital seeks $500 million for AI healthcare startups - BloombergCatalio Capital Management, backed by KKR, is seeking $500 million for its second fund to invest in AI healthcare startups. The firm accelerated its Nexus V fund launch from 2027, and its most recent fund closed in July 2025 with over $400 million, with 40% in AI-exposed companies.BloombergKKR-Backed Catalio Seeks $500 Million for AI-Healthcare DealsKKR-backed Catalio Capital Management is seeking $500 million to back AI healthcare startups, its second fundraise in 16 months. The firm said AI technologies are speeding up healthcare innovation, creating category-defining businesses combining AI with biomedicine and clinical care.